Edgewise Therapeutics Inc (EWTX)

[Whalatane]

I used to own CYTK and think I sold it because of this ...from the CYTK trial

Core echocardiographic left ventricular ejection fraction (LVEF) was observed to be <50% in 5 patients (3.5%) on aficamten compared to 1 patient (0.7%) on placebo.

Which means ( I think ) , their drug if approved would have the same REMS requirement as Mevacamten ( MYOK /BMS )
EWTX EDG-7500 HCM drug is expected to have better ejection fraction data which may mean if the drug is finally approved it wouldn't have a REMS requirement .
HCM is only one of their programs
The Canyon trial data in BECKERS is due Q4 ......so early days really with a lot of hurdles ahead

I haven't checked their financials but assume they will raise $ on any successful trial data

As always ... info only , not investment advice . Risk only what U can afford to lose etc etc
Kiwi